Literature DB >> 31199179

L445P mutation on heavy chain stabilizes IgG4 under acidic conditions.

Chang-Ai Xu1, Andrew Z Feng2, Charan K Ramineni2, Matthew R Wallace1, Elizabeth K Culyba1, Kevin P Guay1, Kinjal Mehta1, Robert Mabry1,3, Stephen Farrand1, Jin Xu2, Jianwen Feng1,4.   

Abstract

IgG4, a common type of therapeutic antibody, is less stable during manufacturing processes compared with IgG1. Aggregation and fragmentation are the two main challenges. Here, we report instability of the heavy chain (HC) C-terminal region under acidic conditions, which leads to cleavage and aggregation. Leu445, at the C-terminal region of the HC in IgG4, plays a critical role in its acid-induced fragmentation and subsequent aggregation. We found that mutating HC C-terminal Leu445 to Pro (the corresponding residue in IgG1) in IgG4_CDR-X significantly reduces fragmentation and aggregation, while mutating Pro445 to Leu in IgG1_CDR-X promotes fragmentation and aggregation. HC C-terminal Gly446 cleavage was observed in low pH citrate buffer and resulted in further fragmentation and aggregation, whereas, glycine buffer can completely inhibit the cleavage and aggregation. It is proposed that cleavages occur through acid-induced hydrolysis under acidic conditions and glycine stabilizes IgG4 via two main mechanisms: 1) product feedback inhibition of the hydrolysis reaction, and 2) stabilization of protein conformation by direct interaction with the peptide backbone and charged side chains. Experiments using IgG4 molecules IgG4_CDR-Y and IgG4_CDR-Z with the same CH domains as IgG4_CDR-X, but different complementarity-determining regions (CDRs), indicate that the stability of the HC C-terminal region is also closely related to the sequence of the CDRs. The stability of IgG4_CDR-X is significantly improved when binding to its target. Both observations suggest that there are potential interactions between Fab and CH2-CH3 domains, which could be the key factor affecting the stability of IgG antibodies.

Entities:  

Keywords:  C-terminal cleavage; acidic stress; antibody; domain interaction; mutation; stability

Mesh:

Substances:

Year:  2019        PMID: 31199179      PMCID: PMC6748598          DOI: 10.1080/19420862.2019.1631116

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  17 in total

1.  Monoclonal Antibodies Follow Distinct Aggregation Pathways During Production-Relevant Acidic Incubation and Neutralization.

Authors:  Thomas Skamris; Xinsheng Tian; Matthias Thorolfsson; Hanne Sophie Karkov; Hanne B Rasmussen; Annette E Langkilde; Bente Vestergaard
Journal:  Pharm Res       Date:  2015-11-12       Impact factor: 4.200

2.  Conformational and Colloidal Stabilities of Isolated Constant Domains of Human Immunoglobulin G and Their Impact on Antibody Aggregation under Acidic Conditions.

Authors:  Seiki Yageta; Timothy M Lauer; Bernhardt L Trout; Shinya Honda
Journal:  Mol Pharm       Date:  2015-04-23       Impact factor: 4.939

3.  Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass.

Authors:  Martin S Neergaard; Anders D Nielsen; Henrik Parshad; Marco Van De Weert
Journal:  J Pharm Sci       Date:  2013-11-26       Impact factor: 3.534

Review 4.  Fragmentation of monoclonal antibodies.

Authors:  Josef Vlasak; Roxana Ionescu
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

5.  Controlling protein stability: Mechanisms revealed using formulations of arginine, glycine and guanidinium HCl with three globular proteins.

Authors:  Lauren Platts; Robert J Falconer
Journal:  Int J Pharm       Date:  2015-03-27       Impact factor: 5.875

Review 6.  IgG4 breaking the rules.

Authors:  Rob C Aalberse; Janine Schuurman
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

7.  Acid-induced aggregation propensity of nivolumab is dependent on the Fc.

Authors:  Boning Liu; Huaizu Guo; Jin Xu; Ting Qin; Lu Xu; Junjie Zhang; Qingcheng Guo; Dapeng Zhang; Weizhu Qian; Bohua Li; Jianxin Dai; Sheng Hou; Yajun Guo; Hao Wang
Journal:  MAbs       Date:  2016-06-16       Impact factor: 5.857

8.  A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.

Authors:  S Angal; D J King; M W Bodmer; A Turner; A D Lawson; G Roberts; B Pedley; J R Adair
Journal:  Mol Immunol       Date:  1993-01       Impact factor: 4.407

9.  Acetate- and Citrate-Specific Ion Effects on Unfolding and Temperature-Dependent Aggregation Rates of Anti-Streptavidin IgG1.

Authors:  Gregory V Barnett; Vladimir I Razinkov; Bruce A Kerwin; Alexander Hillsley; Christopher J Roberts
Journal:  J Pharm Sci       Date:  2016-02-03       Impact factor: 3.534

10.  Structural determinants of unique properties of human IgG4-Fc.

Authors:  Anna M Davies; Theo Rispens; Pleuni Ooijevaar-de Heer; Hannah J Gould; Roy Jefferis; Rob C Aalberse; Brian J Sutton
Journal:  J Mol Biol       Date:  2013-11-06       Impact factor: 5.469

View more
  1 in total

1.  Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names.

Authors:  Ian Wilkinson; Geoff Hale
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.